Novel Frizzled 7 Antibody Shows Promise Against Wilms Tumor Through Wnt Pathway Disruption
核心洞察
Researchers developed a novel monoclonal antibody (αFZD7-288.1 (搜索)) that specifically targets the Frizzled 7 (搜索) receptor and significantly inhibits Wilms tumor (搜索) growth in preclinical studies.
The antibody disrupts canonical Wnt signaling by reducing active β-catenin (搜索) levels and downregulating key target genes including C-MYC (搜索), AXIN2 (搜索), and CCND1 (搜索).
In vivo xenograft studies demonstrated that αFZD7-288.1 (搜索) treatment at 10 mg/kg significantly reduced tumor volumes with minimal toxicity compared to paclitaxel chemotherapy.
Researchers at Sheba Medical Center have developed a novel monoclonal antibody that targets the Frizzled 7 (搜索) (FZD7 (搜索)) receptor, demonstrating significant anti-tumor activity against Wilms tumor (搜索), the most common pediatric kidney cancer (搜索). The study, published in Frontiers in Bioengineering and Biotechnology, presents compelling preclinical evidence for a targeted therapeutic approach that could improve outcomes while reducing treatment-related toxicity.
Targeting the Wnt Pathway in Pediatric Cancer
Wilms tumor (搜索) affects approximately 1 in 10,000 children and accounts for 6% of childhood cancers. While current combined therapies achieve survival rates of 85-90%, patients who experience disease relapse or metastasis face significantly lower survival rates of approximately 50%. Moreover, survivors often suffer from long-term adverse effects including secondary cancers and late mortality due to intensive chemotherapy and radiation.
The research team, led by investigators from Sheba Cancer Center (搜索), focused on the Frizzled 7 (搜索) receptor, a key component of the Wnt/β-catenin (搜索) signaling pathway that has been implicated in various adult and pediatric cancers. Previous work by the group identified FZD7 (搜索) as a molecular marker of cancer (搜索) stem cells in Wilms tumor (搜索) and suggested its potential as a therapeutic target.
Antibody Development and Characterization
Using epitope mapping of the FZD7 (搜索) receptor, researchers created a cohort of specific monoclonal antibodies. Through systematic screening, they identified clone 288.1 (αFZD7-288.1 (搜索)) as the most promising candidate. This antibody was generated by immunizing against epitope 4 of the C-terminus of the receptor and demonstrated specific binding to FZD7-expressing cells through multiple validation methods including protein immunoprecipitation, Western blot analysis, and flow cytometry.
The specificity of αFZD7-288.1 (搜索) was confirmed through comparison with commercial anti-FZD7 (搜索) antibodies and validation in cells with FZD7 knockdown. Flow cytometry analysis revealed that cells stained positive for αFZD7-288.1 were primarily observed as a subpopulation within cells detected by commercial antibodies, suggesting enhanced specificity.
Mechanism of Action
Treatment with αFZD7-288.1 (搜索) at 5 μg/mL for 48 hours resulted in significant inhibition of the canonical Wnt signaling pathway. The antibody prevented accumulation of active unphosphorylated β-catenin (搜索) protein and reduced its nuclear localization, as demonstrated by immunofluorescence staining.
Gene expression analysis revealed downregulation of key Wnt pathway components and target genes. CCND1 (搜索) (Cyclin D1), previously connected to cell cycle arrest, was significantly reduced. C-MYC (搜索), a well-described oncogene and Wnt pathway target, was also repressed. Additionally, the treatment led to decreased expression of β-catenin (搜索), FZD7 (搜索), and Wnt inhibitors DKK1 (搜索) and sFRP1 (搜索).
Anti-Tumor Effects In Vitro
The functional impact of αFZD7-288.1 (搜索) treatment was substantial across multiple cellular processes. Treated Wilms tumor (搜索) cells demonstrated significantly longer doubling times (approximately 49 hours compared to 28 hours in controls) and reduced growth rates. MTS assays and Ki67 immunofluorescence staining confirmed decreased proliferation, with only 13% Ki67-positive cells in treated samples compared to 29% in controls.
The antibody also induced significant cell death, as evidenced by increased annexin V staining and trypan blue exclusion assays. Migration capacity was markedly reduced in scratch assays, and sphere formation ability - a hallmark of cancer (搜索) stem cells - was significantly impaired in treated cells.
Impact on Cancer Stem Cell Markers
A particularly significant finding was the antibody's effect on cancer (搜索) stem cell populations. Immunofluorescence analysis revealed strong co-localization between FZD7 (搜索) and NCAM1 (搜索), a Wilms tumor (搜索) cancer stem cell marker. Treatment with αFZD7-288.1 (搜索) led to significant downregulation of key cancer stem cell markers including NCAM1, SIX2 (搜索), CITED1 (搜索), and ALDH1 (搜索). These markers overlap with populations resembling fetal nephron progenitors known to promote Wilms tumor progression, suggesting the antibody disrupts the stem-like compartment that often drives treatment resistance.
Promising In Vivo Results
The most compelling evidence came from xenograft studies using NOD/SCID mice. Treatment with 10 mg/kg αFZD7-288.1 (搜索) administered intravenously every other day significantly inhibited tumor growth starting after the second injection (p < 0.01). Remarkably, three of five treated tumors showed reduced volume compared to initial tumor size, while the remaining two continued to grow but at substantially slower rates than controls.
The antibody's efficacy was comparable to paclitaxel (15 mg/kg), a standard chemotherapy agent, but with a crucial advantage: no significant weight loss or toxicity was observed in αFZD7-288.1 (搜索)-treated mice. In contrast, paclitaxel-treated mice experienced severe weight loss exceeding 20%, necessitating early termination of the experiment.
Flow cytometry analysis of treated tumors revealed a significant 0.445-fold decrease in FZD7 (搜索)-expressing cells compared to controls. Gene expression analysis confirmed downregulation of canonical Wnt pathway genes including FZD7, β-CATENIN (搜索), AXIN2 (搜索), CCND1 (搜索), C-MYC (搜索), DKK1 (搜索), and sFRP1 (搜索) in treated tumors.
Broader Therapeutic Potential
The researchers also evaluated αFZD7-288.1 (搜索)'s efficacy in other cancer (搜索) types known to have Wnt pathway aberrations. Treatment successfully inhibited canonical Wnt signaling in both melanoma (搜索) (SK-MEL28) and cervical cancer (搜索) (HeLa) cell lines, suggesting potential broader applicability for FZD7 (搜索)-expressing tumors.
Clinical Implications and Future Directions
These findings represent a significant advance in targeted therapy for pediatric cancers. The antibody's ability to specifically target cancer (搜索) stem cells while avoiding the severe toxicities associated with conventional chemotherapy could transform treatment approaches for Wilms tumor (搜索) and potentially other Wnt-dependent cancers.
The researchers acknowledge limitations including small sample sizes and short observation periods in their in vivo studies. They emphasize that larger cohorts and extended follow-up studies will be necessary to fully validate the therapeutic potential of the FZD7 (搜索) antibody.
The study suggests that FZD7 (搜索) represents a valid therapeutic target in Wilms tumor (搜索) through an antibody-mediated approach. Given the antibody's specificity for FZD7 receptors and favorable safety profile demonstrated in preclinical studies, this research provides a strong foundation for advancing toward clinical trials in pediatric oncology.